Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octreotide long-term follow-up in autosomal dominant polycystic kidney disease
2005-005552-41Phase 3Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Mar 2007
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autosomal dominant polycystic kidney disease (ADPKD) comparing Octreotide with Placebo (2 arms). Primary endpoints: Change from baseline in total kidney volume at 1 year and Change from baseline in total kidney volume at 3 years. Started Mar 2007; status: completed.
02
Drugs
octreotide
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on 2005-005552-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005552-41.